香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 授予股份獎勵 謹此提述中國生物科技服務控股有限公司（「本公司」）日期為二零二一年八月十八 日之公告（「該公告」），內容有關本公司於二零二一年八月十八日採納之股份獎勵 計劃（「股份獎勵計劃」）。除另有界定者外，於本公告內所採用的詞彙與該公告內 所界定者具有相同涵義。 本公司董事（「董事」）會（「董事會」）宣佈，於二零二六年三月三十日，根據本公司 薪酬委員會（「薪酬委員會」）之建議，董事會已經議決根據股份獎勵計劃，按零代 價向七名獲選參與者（「承授人」）授予合共4,500,000股獎勵股份（「授予」），相當於 本公告日期之已發行股份總數約0.46%，其須待承授人接納後，方可作實。4,500,000 股獎勵股份乃由受託人運用本公 ...

Financial Performance - The company's revenue for the year ended December 31, 2025, was HKD 73,503,000, representing an increase of 4.2% from HKD 70,509,000 in 2024[4] - Gross profit for the year was HKD 7,726,000, compared to a gross loss of HKD 4,940,000 in the previous year, indicating a significant turnaround[4] - The net loss for the year was HKD 80,841,000, a reduction of 67.9% from a net loss of HKD 251,854,000 in 2024[5] - Revenue from medical laboratory testing and health check services was HKD 35,782,000 in 2025, a decrease of 3.5% from HKD 39,158,000 in 2024[23] - Insurance brokerage service revenue increased to HKD 37,570,000 in 2025, up 22.5% from HKD 30,600,000 in 2024[23] - The company reported a total loss of approximately HKD 80,841,000 for the year ending December 31, 2025[15] - The total loss before tax for the year ended December 31, 2025, was HKD 81,697,000, with a net loss of HKD 80,841,000 after tax credits[27] - The company’s annual loss for 2025 was HKD 68,778,000, a reduction from a loss of HKD 198,146,000 in 2024, indicating an improvement of approximately 65.3%[37] Assets and Liabilities - Total assets increased to HKD 702,575,000 in 2025, up from HKD 529,955,000 in 2024, reflecting a growth of 32.6%[6] - The total liabilities increased to HKD 546,830,000, up from HKD 287,567,000, representing an increase of 90%[7] - The equity attributable to the owners of the company decreased to HKD 191,410,000 from HKD 264,942,000, a decline of 27.7%[7] - As of December 31, 2025, the company's current liabilities exceeded its current assets by approximately HKD 266,069,000[15] - The total borrowings and lease liabilities were approximately HKD 338,012,000 and HKD 12,620,000, respectively, with cash and bank balances of about HKD 12,083,000[15] - The total assets as of December 31, 2025, amounted to HKD 702,575,000, with significant contributions from non-current assets in mainland China at HKD 571,984,000[31] - The total liabilities as of December 31, 2025, were HKD 546,830,000, with significant liabilities in the boron neutron capture therapy segment at HKD 227,889,000[27] Cash Flow and Financing - The company's cash and cash equivalents decreased to HKD 12,083,000 from HKD 18,913,000, a decline of 36.4%[6] - The company believes it will have sufficient working capital to meet its operational needs and financial obligations for the foreseeable future[16] - The company raised $35,000,000 (equivalent to HKD 272,440,000) through the issuance of convertible bonds to a subscriber, with the bonds maturing in four years[19] - The company secured a loan of up to RMB 180,000,000 from Hainan Rural Commercial Bank for operational purposes, guaranteed by the company and its chairman[75] - The company obtained bank loans of approximately HKD 141,087,000 as of December 31, 2025, significantly increased from HKD 13,259,000 in 2024[95] Operational Highlights - The company is engaged in providing medical laboratory testing services and health check services in Hong Kong, and cancer immunotherapy and health management services in China[13] - The company is also involved in the sale and distribution of health-related and pharmaceutical products in China and Hong Kong[13] - The company has committed to constructing and operating a cancer treatment center utilizing the NeuCure® boron neutron capture therapy system, with construction entering its final stages and expected to be ready for trial operations in Q1 2026[62] - The company plans to initiate the second phase of clinical trials for its LY007 cell injection product by the end of 2026, which is the first CAR-T therapy approved for clinical trials in China targeting CD20[60] - The company has strategically decided to reallocate resources from the sales and distribution of healthcare-related and pharmaceutical products to higher-margin and higher-growth segments, such as boron neutron capture therapy[61] Research and Development - Research and development costs were reduced to HKD 17,201,000 from HKD 33,309,000, a decrease of 48.3%[4] - The company recorded a net foreign exchange gain of HKD 7,700,000 in 2025, a recovery from a loss of HKD 11,152,000 in 2024[24] - The company confirmed impairment losses of approximately HKD 52,713,000 related to boron neutron capture therapy equipment damaged in a storm, with insurance claims recognized as compensation income[24] - The group recorded an impairment loss of approximately HKD 6,731,000 for right-of-use assets in fiscal year 2025 due to new lease agreements for the operations of DVF Group[70] Corporate Governance - The company is listed on the GEM of the Hong Kong Stock Exchange[14] - The financial statements are prepared in accordance with applicable Hong Kong Financial Reporting Standards[15] - The audit committee has reviewed the consolidated financial statements for the fiscal year 2025[106] - The company and its subsidiaries did not purchase, sell, or redeem any listed securities during the fiscal year ending December 31, 2025[109] - The board of directors has undergone changes, with Dr. Yin Ye appointed as an executive director and Dr. Zhang Xiao appointed as an independent non-executive director[105] Market Position and Future Outlook - The year 2025 is identified as a critical year for the company, with significant breakthroughs in its core businesses of boron neutron capture therapy and CAR-T, laying a solid foundation for future growth[81] - The boron neutron capture therapy center in Hainan is set to begin trial operations in February 2026, serving as a demonstration center and a cornerstone for a national network of treatment centers[81] - The CAR-T division has launched China's first clinically approved CD20-targeted CAR-T therapy, marking a significant step towards commercialization, with positive clinical data supporting its efficacy and safety[82]

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本通告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 於本公告日期，董事會包括四名執行董事，即劉小林先生（主席）、何詢先生、 黃嵩先生及尹燁博士；及三名獨立非執行董事，即鄢國祥先生、郭圓濤博士及 張曉博士。 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 董事會會議通告 中國生物科技服務控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣 佈將於二零二六年三月二十七日（星期五）舉行董事會會議，以（其中包括）考慮及 批准本公司及其附屬公司截至二零二五年十二月三十一日止年度之經審核綜合全 年業績，並考慮派付末期股息（如有）。 承董事會命 中國生物科技服務控股有限公司 主席兼執行董事 劉小林 香港，二零二六年三月六日 CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 本通告的資料乃遵照《香港聯合交易所有限公司的GEM證券上市規則》而刊載，旨 在提供有關本公司的資料； ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 1 由於本公司正在編製二零二五財政年度之經審核綜合全年業績，因此，於本公告 內所載的資料僅基於董事會參照最新管理賬目所作出之初步評估，而截至本公告 日期為止，其尚未最終訂定。有關本集團財務資料之詳情將會於本公司之全年業 績公告內披露，其預期將會於二零二六年三月底刊發。 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 盈利警告－虧損減少 本公告乃由中國生物科技服務控股有限公司（「本公司」，連同其附屬公司統稱為「本 集團」）根據香港聯合交易所有限公司GEM證券上市規則（「GEM上市規則」）第 17.10條及香港法例第571章《證券及期貨條例》第XIVA部項下之內幕消息條文（定 義見上市規則）而作出。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者， 根據對本集團截至二零二五年十二月三十一日止年度（「二零二五財政年度」）之未 經審核綜合管理賬目（「管 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生物科技服務控股有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08037 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.1 HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.1 HKD | | 200,000,000 | 本月底法定/註冊股本總額： HKD 200,00 ...

Group 1 - The latest shareholder equity disclosures were made by NetEase Cloud Music, CICC, Aisiji Group, and China Biotechnology Services on February 24, 2026 [1] Group 2 - NetEase Cloud Music (09899) held 130 million shares, maintaining a holding percentage of 59.54%, slightly up from 59.50% in the previous disclosure [2] - CICC (03908) reported a decrease in shares held by Tencent Holdings from 95.8067 million to 95.1567 million, resulting in a holding percentage of 4.99%, down from 5.03% [2] - Aisiji Group (08507) saw a reduction in shares held by Wu Qifeng and Three Apple Industry Holdings from 253 million to 251 million, with a holding percentage of 62.86%, down from 63.36% [2] - China Biotechnology Services (08037) experienced a significant increase in shares held by Gong Hongjia and Wealth Strategy Holding Limited from 410 million to 823 million, resulting in a holding percentage of 84.30%, up from 42.02% [2]

Group 1 - The core point of the article is that China Biotechnology Services has completed the issuance of convertible bonds totaling $35 million, with all conditions of the subscription agreement met [1] - The convertible bonds were issued on February 20, 2026, according to the terms and conditions of the subscription agreement [1] - Prior to the issuance of the new convertible bonds, there remains an outstanding principal amount of $6 million from the 2024 convertible bonds, which can be converted into a total of 39.25 million shares at a conversion price of HKD 1.20 per share [1]

Group 1 - The company has completed the issuance of convertible bonds totaling $35 million, with all conditions of the subscription agreement met [1] - Prior to the issuance of the new convertible bonds, there remains an outstanding principal amount of $6 million from the 2024 convertible bonds, which can be converted into approximately 39.25 million shares at a conversion price of HKD 1.20 per share [1]

Core Viewpoint - China Biotechnology Services (08037) has successfully completed the issuance of convertible bonds totaling $35 million, with all conditions of the subscription agreement met as of February 20, 2026 [1] Group 1: Convertible Bonds Issuance - The company issued convertible bonds with a principal amount of $35 million, completing the issuance as per the terms of the subscription agreement [1] - Prior to this issuance, there was an outstanding principal amount of $6 million from the 2024 convertible bonds, which can be converted into a total of 39.25 million shares at a conversion price of HKD 1.20 per share [1] - Following the completion of the new convertible bond issuance, the conversion price for the 2024 convertible bonds has been adjusted from HKD 1.20 to HKD 1.11 per share, effective from February 20, 2026 [1] Group 2: Share Issuance and Terms - The maximum number of shares to be issued upon full conversion of the 2024 convertible bonds is 42.432 million shares, effective from the completion date of the new convertible bond issuance [1] - All other terms of the 2024 convertible bonds remain unchanged despite the adjustment in the conversion price [1]

中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考之用，並不構成收購、購買或認購本公司任何證券的要約或邀請。 CHINA BIOTECH SERVICES HOLDINGS LIMITED (1) 完成根據特別授權發行可轉換債券； 及 (2) 有關未償還二零二四年可轉換債券之調整 茲提述中國生物科技服務控股有限公司（「本公司」）日期為二零二六年一月二十二 日之通函（「該通函」），內容有關（其中包括）根據特別授權建議發行可轉換債券。 除於本公告內另有說明者外，本公告所用詞彙與該通函內所界定者具有相同涵義。 完成根據特別授權發行可轉換債券 董事會欣然宣佈，認購協議所載之所有先決條件均已達成，向認購人發行本金總 額為35,000,000美元之可換股債券已於二零二六年二月二十日根據認購協議之條 款及條件完成。 1 對本公司股權架構之影響 本公司 ...